Mainz Biomed NV (MYNZ)
(Delayed Data from NSDQ)
$0.69 USD
+0.03 (4.50%)
Updated Jun 12, 2024 03:59 PM ET
After-Market: $0.67 -0.02 (-2.90%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MYNZ 0.69 +0.03(4.50%)
Will MYNZ be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for MYNZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYNZ
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
MYNZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
Other News for MYNZ
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Buy Rating Reiterated for Mainz Biomed B.V. on Strong ColoAlert Clinical Data Despite Market Pressures
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
Mainz Biomed presents data from pooled study at ASCO 2024